Geron Corporation Net Assets

Latest as of June 2026: $218.61 Million USD

Geron Corporation net assets. Based on the latest financial reports, Geron Corporation (GERN) has net assets worth $218.61 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($519.01 Million) and total liabilities ($300.39 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore net asset growth rate of Geron Corporation to track the company's year-over-year net asset growth rate.

Key Net Assets Metrics

Metric Value
Current Net Assets $218.61 Million
% of Total Assets 42.12%
Annual Growth Rate 8.1%
5-Year Change 78.67%
10-Year Change 84.57%
Growth Volatility 73.3

Net Assets of Geron Corporation (1996–2025)

Net assets of Geron Corporation from 1996 to 2025. This chart illustrates how Geron Corporation's net assets have evolved over time, based on quarterly financial data. See GERN net asset quality index to measure how much of total assets are equity-financed.

Annual Net Assets for Geron Corporation (1996–2025)

The table below shows the annual net assets of Geron Corporation from 1996 to 2025. For live market cap and overall valuation, see Geron Corporation market cap and net worth.

Year Net Assets Change
2025-12-31 $225.87 Million -19.42%
2024-12-31 $280.32 Million +13.06%
2023-12-31 $247.95 Million +209.94%
2022-12-31 $80.00 Million -36.72%
2021-12-31 $126.42 Million -40.07%
2020-12-31 $210.95 Million +56.08%
2019-12-31 $135.16 Million -23.96%
2018-12-31 $177.73 Million +71.23%
2017-12-31 $103.80 Million -15.18%
2016-12-31 $122.38 Million -13.89%
2015-12-31 $142.13 Million +8.73%
2014-12-31 $130.71 Million +118.74%
2013-12-31 $59.76 Million -30.23%
2012-12-31 $85.65 Million -41.57%
2011-12-31 $146.60 Million -23.94%
2010-12-31 $192.74 Million +11.68%
2009-12-31 $172.58 Million +2.45%
2008-12-31 $168.46 Million -18.10%
2007-12-31 $205.67 Million +18.26%
2006-12-31 $173.92 Million -8.80%
2005-12-31 $190.71 Million +56.23%
2004-12-31 $122.06 Million +14.80%
2003-12-31 $106.32 Million +257.50%
2002-12-31 $29.74 Million -51.67%
2001-12-31 $61.54 Million -3.72%
2000-12-31 $63.92 Million +143.96%
1999-12-31 $26.20 Million -20.12%
1998-12-31 $32.80 Million +55.45%
1997-12-31 $21.10 Million -10.59%
1996-12-31 $23.60 Million --

Equity Component Analysis

This analysis shows how different components contribute to Geron Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 181934100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Geron Corporation Net Assets Breakdown (December 2025)

Geron Corporation net assets breakdown by equity component as of December 2025.

Component Amount Percentage
Common Stock $640.00K 0.28%
Other Comprehensive Income $269.00K 0.12%
Other Components $2.08 Billion 921.23%
Total Equity $225.87 Million 100.00%

Geron Corporation Competitors by Market Cap

The table below lists competitors of Geron Corporation ranked by their market capitalization.

Company Market Cap
TPI POLENE POWER
BK:TPIPP-R
 $596.95 Million
Zhe Jiang Kangsheng Co Ltd
SHE:002418
 $596.98 Million
CREOTECH INS.S.A. ZY -10
F:5OB
 $597.14 Million
EPC Groupe
PA:EXPL
 $597.32 Million
Shenzhen Longtech Smart Control Co. Ltd.
SHE:300916
 $596.88 Million
Sagimet Biosciences Inc. Series A Common Stock
NASDAQ:SGMT
 $596.82 Million
Shenzhen Sinovatio Technology Co Ltd Class A
SHE:002912
 $596.67 Million
Zhejiang Langdi Group Co Ltd
SHG:603726
 $596.58 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Geron Corporation's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 280,320,000 to 225,872,000, a change of -54,448,000 (-19.4%).
  • Net loss of 85,782,000 reduced equity.
  • Other comprehensive income increased equity by 8,000.
  • Other factors increased equity by 31,326,000.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income $-85.78 Million -37.98%
Other Comprehensive Income $8.00K +0.0%
Other Changes $31.33 Million +13.87%
Total Change $- -19.42%

Book Value vs Market Value Analysis

This analysis compares Geron Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 2.74x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has increased from 0.30x to 2.74x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1996-12-31 $3.05 $0.93 x
1997-12-31 $2.00 $0.93 x
1998-12-31 $2.87 $0.93 x
1999-12-31 $1.69 $0.93 x
2000-12-31 $3.06 $0.93 x
2001-12-31 $2.78 $0.93 x
2002-12-31 $1.21 $0.93 x
2003-12-31 $3.43 $0.93 x
2004-12-31 $2.72 $0.93 x
2005-12-31 $3.29 $0.93 x
2006-12-31 $2.63 $0.93 x
2007-12-31 $2.77 $0.93 x
2008-12-31 $2.15 $0.93 x
2009-12-31 $1.96 $0.93 x
2010-12-31 $1.97 $0.93 x
2011-12-31 $1.18 $0.93 x
2012-12-31 $0.67 $0.93 x
2013-12-31 $0.47 $0.93 x
2014-12-31 $0.85 $0.93 x
2015-12-31 $0.87 $0.93 x
2016-12-31 $0.77 $0.93 x
2017-12-31 $0.65 $0.93 x
2018-12-31 $1.01 $0.93 x
2019-12-31 $0.71 $0.93 x
2020-12-31 $0.78 $0.93 x
2021-12-31 $0.39 $0.93 x
2022-12-31 $0.21 $0.93 x
2023-12-31 $0.43 $0.93 x
2024-12-31 $0.43 $0.93 x
2025-12-31 $0.34 $0.93 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Geron Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -37.98%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -46.65%
  • • Asset Turnover: 0.32x
  • • Equity Multiplier: 2.53x
  • Recent ROE (-37.98%) is above the historical average (-55.62%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1996 -45.34% -201.89% 0.18x 1.22x $-13.06 Million
1997 -45.50% -131.51% 0.28x 1.24x $-11.71 Million
1998 -32.93% -158.82% 0.15x 1.36x $-14.08 Million
1999 -177.10% -859.26% 0.08x 2.43x $-49.02 Million
2000 -71.71% -693.49% 0.06x 1.78x $-52.22 Million
2001 -68.36% -1162.24% 0.04x 1.56x $-48.23 Million
2002 -114.01% -2716.99% 0.02x 2.04x $-36.88 Million
2003 -28.11% -2545.40% 0.01x 1.11x $-40.52 Million
2004 -65.87% -7635.80% 0.01x 1.08x $-92.61 Million
2005 -17.58% -11561.38% 0.00x 1.06x $-52.60 Million
2006 -18.03% -957.13% 0.01x 1.27x $-48.76 Million
2007 -17.84% -481.46% 0.03x 1.06x $-57.26 Million
2008 -36.82% -2212.67% 0.02x 1.05x $-78.87 Million
2009 -40.67% -4066.28% 0.01x 1.05x $-87.44 Million
2010 -57.79% -3125.93% 0.02x 1.21x $-130.65 Million
2011 -66.06% -3972.64% 0.02x 1.09x $-111.51 Million
2012 -80.42% -2542.67% 0.03x 1.17x $-77.45 Million
2013 -64.23% -2991.35% 0.02x 1.13x $-44.35 Million
2014 -27.29% -3093.67% 0.01x 1.32x $-48.74 Million
2015 0.03% 0.13% 0.24x 1.05x $-14.17 Million
2016 -24.14% -479.34% 0.05x 1.06x $-41.77 Million
2017 -26.89% -2621.22% 0.01x 1.06x $-38.30 Million
2018 -15.20% -2534.43% 0.01x 1.04x $-44.79 Million
2019 -47.02% -13815.43% 0.00x 1.22x $-77.07 Million
2020 -35.85% -29888.14% 0.00x 1.28x $-96.71 Million
2021 -91.85% -8335.39% 0.01x 1.79x $-128.75 Million
2022 -177.38% -23808.89% 0.00x 2.38x $-149.90 Million
2023 -74.26% -77690.72% 0.00x 1.59x $-208.92 Million
2024 -62.28% -226.73% 0.13x 2.12x $-202.60 Million
2025 -37.98% -46.65% 0.32x 2.53x $-108.37 Million

Industry Comparison

This section compares Geron Corporation's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $186,602,403
  • Average return on equity (ROE) among peers: -32.23%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Geron Corporation (GERN) $218.61 Million -45.34% 1.37x $596.92 Million
Aardvark Therapeutics, Inc. Common Stock (AARD) $-54.64 Million 0.00% 0.00x $26.13 Million
Abcellera Biologics Inc (ABCL) $1.23 Billion 12.85% 0.25x $3.53 Billion
Abeona Therapeutics Inc (ABEO) $-17.61 Million 0.00% 0.00x $243.03 Million
Acumen Pharmaceuticals Inc (ABOS) $-11.42 Million 0.00% 0.00x $17.31 Million
Abpro Holdings, Inc. (ABP) $-22.46 Million 0.00% 0.00x $2.00 Million
Absci Corp (ABSI) $179.13 Million -57.56% 0.19x $1.41 Billion
Arbutus Biopharma Corp (ABUS) $30.03 Million -30.65% 0.08x $792.42 Million
ABVC Biopharma Inc (ABVC) $2.46 Million -172.46% 1.68x $26.12 Million
Abivax SA American Depositary Shares (ABVX) $48.18 Million -23.29% 0.12x $7.41 Billion
ACADIA Pharmaceuticals Inc (ACAD) $479.08 Million -51.18% 0.13x $3.53 Billion

About Geron Corporation

NASDAQ:GERN USA Biotechnology
Market Cap
$596.92 Million
Market Cap Rank
#11001 Global
#2885 in USA
Share Price
$0.93
Change (1 day)
+4.39%
52-Week Range
$0.89 - $1.95
All Time High
$6.38
Categories
Companies in USA Biotechnology
About

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lowe… Read more